Denosumab biosimilar is a monoclonal antibody commercialized by Organon & Co, with a leading Phase III program in Post Menopausal Osteoporosis. According to Globaldata, it is involved in 2 clinical trials, which were completed. GlobalData uses proprietary data and analytics to provide a complete picture of Denosumab biosimilar’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Denosumab biosimilar is expected to reach an annual total of $182 mn by 2040 globally based off GlobalData’s Revenue Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Denosumab biosimilar Overview
Denosumab biosimilar (HLX-14) is under development for the treatment of giant cell tumor, bone metastases and postmenopausal women with osteoporosis at high risk for fracture. The drug candidate is a humanized monoclonal antibody. It is administered through subcutaneous route. The drug candidate acts by targeting receptor activator of nuclear factor kappa B ligand (RANKL).
Organon & Co Overview
Organon & Co (Organon) is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium acetate injection, chorionic gonadotropin and others. Organon distributes and sells its products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. It collaborates with pharmaceutical and biopharmaceutical businesses to market its products. It has operations in Europe North America, Asia Pacific, Latin America, Middle East, CIS and Africa. Organon is headquartered in Jersey City, New Jersey, the US.
The company reported revenues of (US Dollars) US$6,263 million for the fiscal year ended December 2023 (FY2023), an increase of 1.4% over FY2022. In FY2023, the company’s operating margin was 10.7%, compared to an operating margin of 18.2% in FY2022. In FY2023, the company recorded a net margin of 16.3%, compared to a net margin of 14.9% in FY2022.
The company reported revenues of US$1,607 million for the second quarter ended June 2024, a decrease of 0.9% over the previous quarter.
For a complete picture of Denosumab biosimilar’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
